# Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu

> **NCT03789539** · PHASE1 · UNKNOWN · sponsor: **VA Pharma Limited Liability Company** · enrollment: 54 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **BIOLOGICAL:** LD Universal Influenza Vaccine Uniflu
- **BIOLOGICAL:** HD Universal Influenza Vaccine Uniflu
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03789539
- **Lead sponsor:** VA Pharma Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-02
- **Primary completion:** 2018-12-02
- **Final completion:** 2018-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789539, "Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT03789539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*